Condition: Relapsing Remitting Multiple Sclerosis · Sponsor: Haukeland University Hospital
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
This description comes directly from the study's public registry record.
Trond T. Serkland, M.D. · 004755975563 · trond.tretteberg.serkland@helse-bergen.no
Silje Skrede, M.D., PhD · silje.skrede@helse-bergen.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital, Deparment of medical biochemistry and pharmacology | Bergen, Vestland, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663111